Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case

ABSTRACT MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Finsterer,Josef
Lenguaje:	English
Publicado:	Sociedad Médica de Santiago 2020
Materias:	Drug-Related Side Effects and Adverse Reactions Leukopenia Rhabdomyolysis
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020001101684
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872020001101684
record_format	dspace
spelling	oai:scielo:S0034-988720200011016842021-04-04Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one caseFinsterer,Josef Drug-Related Side Effects and Adverse Reactions Leukopenia Rhabdomyolysis ABSTRACT MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after using interferon without benefit. Shortly after starting trametinib/dabrafenib, she experienced an inability to abduct the left eye. Eight days after starting this therapy the patient experienced loss of appetite, vomiting, diarrhea, vertigo, and fever of 40°C. Two days later she experienced visual loss, requiring permanent support for her daily activities. Two further days later myoglobinuria appeared in the absence of myalgias or muscle weakness but accompanied by marked tiredness and inactivity. She could not eat or drink during four days prior to admission. The patient suspected an adverse effect of trametinib/dabrafenib and discontinued it 2 days prior to admission. Thereafter, she experienced an almost complete remission of the deficits except for ocular muscle weakness and visual impairment.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.148 n.11 20202020-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020001101684en10.4067/S0034-98872020001101684
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Drug-Related Side Effects and Adverse Reactions Leukopenia Rhabdomyolysis
spellingShingle	Drug-Related Side Effects and Adverse Reactions Leukopenia Rhabdomyolysis Finsterer,Josef Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case
description	ABSTRACT MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after using interferon without benefit. Shortly after starting trametinib/dabrafenib, she experienced an inability to abduct the left eye. Eight days after starting this therapy the patient experienced loss of appetite, vomiting, diarrhea, vertigo, and fever of 40°C. Two days later she experienced visual loss, requiring permanent support for her daily activities. Two further days later myoglobinuria appeared in the absence of myalgias or muscle weakness but accompanied by marked tiredness and inactivity. She could not eat or drink during four days prior to admission. The patient suspected an adverse effect of trametinib/dabrafenib and discontinued it 2 days prior to admission. Thereafter, she experienced an almost complete remission of the deficits except for ocular muscle weakness and visual impairment.
author	Finsterer,Josef
author_facet	Finsterer,Josef
author_sort	Finsterer,Josef
title	Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case
title_short	Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case
title_full	Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case
title_fullStr	Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case
title_full_unstemmed	Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case
title_sort	trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. report of one case
publisher	Sociedad Médica de Santiago
publishDate	2020
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020001101684
work_keys_str_mv	AT finstererjosef trametinibanddabrafenibinducedrhabdomyolysisrenalfailureandvisuallossreportofonecase
_version_	1718437167316860928

Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case

Ejemplares similares